By: IPP Bureau
Last updated : September 01, 2024 5:13 pm
The approval further adds to Biocon’s portfolio of complex drug products
Biocon Pharma Limited, a wholly owned subsidiary of Biotech Limited, has received approval of its ANDA for Daptomycin for injection (500mg vial), from the U.S Food and Drug Administration (USFDA).
This product is indicated for use in the treatment of complicated skin and skin structure infections (cSSSI). It is also used to treat Staphylococcus aureus infections in the bloodstream (bacteremia), including right-sided infective endocarditis in adult patients.
The approval further adds to Biocon’s portfolio of complex drug products.